Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

US Army
AstraZeneca
Accenture
Moodys
Dow
Colorcon
Johnson and Johnson
Baxter
Merck

Generated: December 11, 2018

DrugPatentWatch Database Preview

Meropenem - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for meropenem and what is the scope of meropenem patent protection?

Meropenem is the generic ingredient in four branded drugs marketed by Acs Dobfar, Acs Dobfar Spa, Amneal Pharms, Aurobindo Pharma Ltd, Daewoong Pharm Co, Gland Pharma Ltd, Hospira Inc, Sandoz, Savior Lifetec Corp, Pfizer, B Braun Medical Inc, and Rempex Pharms, and is included in twelve NDAs. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

There are thirty-two drug master file entries for meropenem. Thirteen suppliers are listed for this compound.

Pharmacology for meropenem
Synonyms for meropenem
(1R,5S,6S)-2-[(3S,5S)-5-(dimethylaminocarbonyl)pyrrolidin-3-ylthio]-6-[(R)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylic acid
(1R,5S,6S)-2-[(3S,5S)-5-(dimethylaminocarbonyl)pyrrolidin-3-ylthio]-6-[(R)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylic acid trihydrate
(1R,5S,6S)-2-[(3S,5S)-5-DIMETHYLAMINOCARBONYLPYRROLIDIN-3-YLTHIO]-6-[(R)-1-HYDROXYETHYL]-1-METHYLCARBAPEN-2-EM-3-CARBOXYLIC ACID
(2S,3R,4R)-2-[(1S,2R)-1-carboxy-2-hydroxypropyl]-4-{[(3S,5R)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-3-methyl-3,4-dihydro-2H-pyrrole-5-carboxylic acid
(4R,5S,6S)-3-(((3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl)thio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
(4R,5S,6S)-3-[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
(4R,5S,6S)-3-[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl-6-[(1S)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
(4R,5S,6S)-3-[[(3S,5S)-5-(dimethylaminocarbonyl)-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
(4R,5S,6S)-3-[[(3S,5S)-5-(Dimethylcarbamoyl)pyrrol
(4R,5S,6S)-3-[[(3S,5S)-5-(Dimethylcarbamoyl)pyrrolidin-3-yl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
(4R,5S,6S)-3-[[(3S,5S)-5-[(dimethylamino)carbonyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
(4r,5s,6s)-3-{[(3s,5s)-5-(Dimethylcarbamoyl)pyrrolidin-3-Yl]sulfanyl}-6-[(1r)-1-Hydroxyethyl]-4-Methyl-7-Oxo-1-Azabicyclo[3.2.0]hept-2-Ene-2-Carboxylic Acid
(4R,5S,6S)-3-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]thio}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
(5S,6S)-3-((3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-ylthio)-6-((S)-1-hydroxyethyl)-4-methyl-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid
(6S)-2-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-6-[(1R)-1-hydroxyethyl]-1beta-methyl-2,3-didehydro-1-carbapenam-3-carboxylic acid
036M032
1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-(((3S,5S)-5-((dimethylamino)carbonyl)-3-pyrrolidinyl)thio)-6-((1R)-1-hydroxyethyl)-4-methyl-7-oxo-, (4R,5S,6S)-
119478-56-7
96036-03-2
96036-03-2 (anhydr.)
AB0012458
AB00514051-02
AB00698370-05
AB2000075
AJ-45665
AK-50519
AKOS015920140
AN-14469
Antibiotic SM 7338
BDBM50129062
BR-50519
CAS-96036-03-2
CCG-100850
CHEBI:43968
CS-1865
CTK8G0800
D0O5FY
DB00760
DMJNNHOOLUXYBV-PQTSNVLCSA-N
DSSTox_CID_25526
DSSTox_GSID_45526
DSSTox_RID_80930
DTXSID7045526
Epitope ID:195064
FT-0630992
HMS2098M14
HSDB 8019
HY-13678
ICI 194660
ICI-194660
J10087
KS-5224
M05727
M2279
Mepem (TN)
MEPM
MERONEM
Meronem (TN)
Meropen
Meropen (TN)
Meropenem (INN)
Meropenem [INN]
Meropenem anhydrous
Meropenem Hydrate
Meropenem trihydrate, Antibiotic for Culture Media Use Only
Meropenem trihydrochloride
Meropenemum
Meropenemum trihydricum
Merrem
Merrem (TN)
Merrem I.V. (TN)
Merrem IV
Merrem;Meronem
MFCD08600005
NC00100
NCGC00016962-01
NCGC00253670-01
NCGC00262579-02
Neopenem (TN)
PubChem17275
S-3680
SC-18058
SC-45234
SCHEMBL34442
SM 7338
SM-7338
SR-01000762894
SR-01000762894-4
ST24025110
Tox21_110715
Tox21_110715_1
Tox21_113794
UNII-YOP6PX0BAO
YOP6PX0BAO
ZINC3808779

US Patents and Regulatory Information for meropenem

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer MERREM meropenem INJECTABLE;INJECTION 050706-003 Jun 21, 1996 AP RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Savior Lifetec Corp MEROPENEM meropenem INJECTABLE;INJECTION 206086-002 Apr 19, 2016 AP RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Acs Dobfar MEROPENEM meropenem INJECTABLE;INJECTION 091404-002 Oct 26, 2011 AP RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Daewoong Pharm Co MEROPENEM meropenem INJECTABLE;INJECTION 204854-001 Dec 18, 2015 AP RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for meropenem

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer MERREM meropenem INJECTABLE;INJECTION 050706-001 Jun 21, 1996 ➤ Try a Free Trial ➤ Try a Free Trial
Pfizer MERREM meropenem INJECTABLE;INJECTION 050706-003 Jun 21, 1996 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Cipla
Farmers Insurance
Harvard Business School
Covington
Chinese Patent Office
McKinsey
Fuji
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.